Safety and Efficacy Assessment of NucleoCapture Selective DNA Adsorber in Humans
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Santersus AG
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Serum urea change over time
研究概览
简要总结
This open non-randomized controlled single center study investigates to what extent the removal of circulating Neutrophil Extracellular Traps (NETs) from blood by NucleoCapture device has a positive effect on the treatment of patients with sepsis and sepsis-associated AKI (SA-AKI).
详细描述
The term "sepsis" refers to a clinical syndrome in which a dysregulation of the host's inflammatory reaction to infection leads to a life-threatening of organ dysfunctions. Sepsis and septic shock are major causes of death in intensive care units worldwide. Sepsis remains the most important cause of AKI in the intensive care unit (ICU) with 15%-20% of patients with sepsis-associated AKI (SA-AKI) prescribed RRT . In addition to association with short term mortality, AKI is also linked to the later development of CKD, ESRD, and long-term increased risk of death
NETosis is a unique form of neutrophil cell death that is characterized by the release of neutrophil extracellular traps (NETs) composed of DNA web-like structures decorated with highly cytotoxic protein components. Release of NETs leads to bystander tissue damage (including the kidneys) and drives a fatal course of disease in sepsis patients.
The plasmapheresis is a medical procedure, where pathogenic components are being removed from the blood by adsorbers outside the body in an extracorporeal circulation. For removal of the pathogenic substances the plasma is separated from the blood to pass the adsorber. The purified plasma is merged with the solid blood components thereafter and returned to the patient. The NucleoCapture device provide highly selective removal of neutrophil extracellular traps from human blood during plasmapheresis procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 18 and ≤ 75 years of age.
- •Meet the clinical criteria of sepsis according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3))
- •Written informed consent
排除标准
- •A terminal state
- •Active bleeding or uncontrolled acute massive bleeding
结局指标
主要结局
Serum urea change over time
时间窗: from [start of treatment] through 28 days after
Change of urea in serum over time for each patient and in average in group
Incidence of acute kidney injury (AKI)
时间窗: from [start of treatment] through 28 days after
Incidence of acute kidney injury (AKI) in accordance with Kidney Disease Improving Global Outcomes (KDIGO) definitions for AKI
Urine output change
时间窗: from [start of treatment] through 28 days after
Change of urine output over time for each patient and in average in group
Severity of acute kidney injury (AKI)
时间窗: from [start of treatment] through 28 days after
Severity of acute kidney injury (AKI) in accordance with KDIGO definitions for AKI
Rate of AKI transition to the more severe stage (for patients with AKI at baseline).
时间窗: from [start of treatment] through 28 days after
Rate of worsening of acute kidney injury (AKI) in accordance with KDIGO AKI classification (Changing stages from 1 to 2, from 2 to 3).
Serum creatinine change over time
时间窗: from [start of treatment] through 28 days after
Change of creatinine in serum over time for each patient and in average in group
次要结局
- qSOFA scores change(from [start of treatment] through 28 days after)
- All-cause mortality(from [start of treatment] through 28 days after)
- SOFA scores change(from [start of treatment] through 28 days after)
